

# Kelly M Chin

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2976590/kelly-m-chin-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

55  
papers

3,416  
citations

23  
h-index

58  
g-index

62  
ext. papers

4,238  
ext. citations

5.3  
avg, IF

5.03  
L-index

#	Paper	IF	Citations
55	Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension. <i>Advances in Therapy</i> , <b>2021</b> , 39, 796	4.1	4
54	The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study. <i>European Journal of Heart Failure</i> , <b>2021</b> ,	12.3	1
53	TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , <b>2021</b> , 11, 20458940211057071	2.7	3
52	Parenteral prostanoids for severe Group 3 pulmonary hypertension with right ventricular dysfunction. <i>Journal of Thoracic Disease</i> , <b>2021</b> , 13, 1466-1475	2.6	
51	Patient and disease characteristics of the first 500 patients with pulmonary arterial hypertension treated with selexipag in real-world settings from SPHERE. <i>Journal of Heart and Lung Transplantation</i> , <b>2021</b> , 40, 279-288	5.8	3
50	The United States Chronic Thromboembolic Pulmonary Hypertension Registry: Protocol for a Prospective, Longitudinal Study. <i>JMIR Research Protocols</i> , <b>2021</b> , 10, e25397	2	1
49	Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study. <i>Respiratory Research</i> , <b>2021</b> , 22, 34	7.3	2
48	Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study. <i>Chest</i> , <b>2021</b> , 160, 277-286	5.3	4
47	Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 1393-1403	15.1	16
46	Hemodynamic effects of fluoxetine in pulmonary arterial hypertension: an open label pilot study. <i>Pulmonary Circulation</i> , <b>2020</b> , 10, 2045894020971954	2.7	4
45	Pulmonary Arterial Hypertension-Symptoms and Impact Questionnaire: feasibility of utilizing one-day versus seven-day symptom reporting. <i>Pulmonary Circulation</i> , <b>2020</b> , 10, 2045894020923957	2.7	0
44	Risk assessment in pulmonary arterial hypertension: Insights from the GRIPHON study. <i>Journal of Heart and Lung Transplantation</i> , <b>2020</b> , 39, 300-309	5.8	19
43	Differentiating Precapillary From Postcapillary Pulmonary Hypertension. <i>Circulation</i> , <b>2019</b> , 140, 712-714	16.7	13
42	"Treat-to-close": Non-repairable ASD-PAH in the adult: Results from the North American ASD-PAH (NAAP) Multicenter Registry. <i>International Journal of Cardiology</i> , <b>2019</b> , 291, 127-133	3.2	20
41	Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension. <i>Circulation</i> , <b>2019</b> , 139, 2440-2450	16.7	32
40	Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study. <i>Journal of Heart and Lung Transplantation</i> , <b>2019</b> , 38, 43-50	5.8	16
39	Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study. <i>European Journal of Heart Failure</i> , <b>2019</b> , 21, 352-359	12.3	26

38	Discordance between Imaging Modalities in the Evaluation of Chronic Thromboembolic Pulmonary Hypertension: A Combined Experience from Two Academic Medical Centers. <i>Annals of the American Thoracic Society</i> , <b>2019</b> , 16, 277-280	4.7	2
37	Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update. <i>European Respiratory Journal</i> , <b>2019</b> , 53,	13.6	148
36	Mortality in Patients With Pulmonary Arterial Hypertension Treated With Continuous Prostanoids. <i>Chest</i> , <b>2018</b> , 154, 532-540	5.3	8
35	Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 752-763	15.1	50
34	Lessons from the COMPASS-3 Study. <i>Pulmonary Circulation</i> , <b>2018</b> , 8, 2045893218757100	2.7	
33	The impact of ambrisentan and tadalafil upfront combination therapy on cardiac function in scleroderma associated pulmonary arterial hypertension patients: cardiac magnetic resonance feature tracking study. <i>Pulmonary Circulation</i> , <b>2018</b> , 8, 2045893217748307	2.7	21
32	Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. <i>American Journal of Cardiovascular Drugs</i> , <b>2018</b> , 18, 37-47	4	39
31	Improvement in Right Ventricular Strain with Ambrisentan and Tadalafil Upfront Therapy in Scleroderma-associated Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2018</b> , 197, 388-391	10.2	24
30	Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. <i>Journal of Heart and Lung Transplantation</i> , <b>2018</b> , 37, 401-408	5.8	12
29	Psychometric Validation of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire: Results of the SYMPHONY Trial. <i>Chest</i> , <b>2018</b> , 154, 848-861	5.3	23
28	Anorexigen-Associated Pulmonary Arterial Hypertension and the Serotonin Hypothesis: A Story Worth Telling. <i>Advances in Pulmonary Hypertension</i> , <b>2018</b> , 17, 63-68	0.5	
27	Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. <i>European Respiratory Journal</i> , <b>2017</b> , 50,	13.6	58
26	Right atrial emptying fraction non-invasively predicts mortality in pulmonary hypertension. <i>International Journal of Cardiovascular Imaging</i> , <b>2016</b> , 32, 1121-30	2.5	16
25	Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy. <i>Drug Design, Development and Therapy</i> , <b>2016</b> , 10, 3747-3754	4.4	9
24	Efficacy and Safety of Exercise Training in Chronic Pulmonary Hypertension: Systematic Review and Meta-Analysis. <i>Circulation: Heart Failure</i> , <b>2015</b> , 8, 1032-43	7.6	70
23	Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2015</b> , 192, 1102-10	10.2	97
22	Long-term therapy with oral treprostinil in pulmonary arterial hypertension failed to lead to improvement in important physiologic measures: results from a single center. <i>Pulmonary Circulation</i> , <b>2015</b> , 5, 513-20	2.7	19
21	Selexipag for the Treatment of Pulmonary Arterial Hypertension. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 2522-33	59.2	521

20	Does treatment response to ambrisentan vary by pulmonary arterial hypertension severity? Implications for clinicians and for the design of future clinical trials. <i>International Journal of Clinical Practice</i> , <b>2014</b> , 68, 568-77	2.9	6
19	Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study. <i>American Heart Journal</i> , <b>2014</b> , 167, 218-225.e1	4.9	21
18	Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 62, D22-33	15.1	584
17	Association of cardiac troponin I with disease severity and outcomes in patients with pulmonary hypertension. <i>American Journal of Cardiology</i> , <b>2013</b> , 111, 1812-7	3	24
16	Left atrial structure and function and clinical outcomes in the general population. <i>European Heart Journal</i> , <b>2013</b> , 34, 278-85	9.5	147
15	Safety recommendations for administering intravenous prostacyclins in the hospital. <i>Critical Care Nurse</i> , <b>2013</b> , 33, 32-9	1.6	18
14	Characterizing the right ventricle: advancing our knowledge. <i>American Journal of Cardiology</i> , <b>2012</b> , 110, 3S-8S	3	24
13	International Classification of Diseases coding changes lead to profound declines in reported idiopathic pulmonary arterial hypertension mortality and hospitalizations: implications for database studies. <i>Chest</i> , <b>2011</b> , 139, 497-504	5.3	53
12	Idiopathic and heritable pulmonary hypertension <b>2011</b> , 207-211		
11	Prostacyclin administration errors in pulmonary arterial hypertension patients admitted to hospitals in the United States: a national survey. <i>Journal of Heart and Lung Transplantation</i> , <b>2010</b> , 29, 841-6	5.8	41
10	Long-term outcomes with ambrisentan monotherapy in pulmonary arterial hypertension. <i>Journal of Cardiac Failure</i> , <b>2010</b> , 16, 121-7	3.3	36
9	Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension. <i>Chest</i> , <b>2009</b> , 135, 130-136	5.3	38
8	Changes in right ventricular structure and function assessed using cardiac magnetic resonance imaging in bosentan-treated patients with pulmonary arterial hypertension. <i>American Journal of Cardiology</i> , <b>2008</b> , 101, 1669-72	3	58
7	Pulmonary arterial hypertension. <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 51, 1527-38	15.1	225
6	Telomere shortening in familial and sporadic pulmonary fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2008</b> , 178, 729-37	10.2	379
5	Central venous blood oxygen saturation monitoring in patients with chronic pulmonary arterial hypertension treated with continuous IV epoprostenol: correlation with measurements of hemodynamics and plasma brain natriuretic peptide levels. <i>Chest</i> , <b>2007</b> , 132, 786-92	5.3	10
4	Chronic Thromboembolic Pulmonary Hypertension <b>2006</b> , 188-209		
3	Is methamphetamine use associated with idiopathic pulmonary arterial hypertension?. <i>Chest</i> , <b>2006</b> , 130, 1657-63	5.3	134

2	The right ventricle in pulmonary hypertension. <i>Coronary Artery Disease</i> , <b>2005</b> , 16, 13-8	1.4	316
1	Bosentan. <i>Expert Review of Cardiovascular Therapy</i> , <b>2004</b> , 2, 175-82	2.5	9